BWI-CTU Researchers Elected to ACTG Network Committees

Date: 11/30/2016

November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:

  • Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
     
  • David Hardy, Whitman-Walker Clincial Trials Site (Washington)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore)
    Non-voting Member, Antiretroviral Therapy Strategies Subcommittee.  
        
  • Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India)
    Investigator, Tuberculosis Transformative Science Group.  
       
  • Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, Tuberculosis Transformative Science Group.  
        
  • Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore)
    Chair, Site Management & Clinical Care Committee

Clinical Trials

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More